Portal de Periódicos da CAPES

Glipizide: A Second‐generation Sulfonylurea Hypoglycemic Agent; Pharmacology, Pharmacokinetics and Clinical Use

1985; Wiley; Volume: 5; Issue: 2 Linguagem: Inglês

10.1002/j.1875-9114.1985.tb03405.x

1875-9114

Harold E. Lebovitz,

Analytical Methods in Pharmaceuticals

Glipizide is a second-generation sulfonylurea in which the substitutions on the arylsulfonylurea nucleus are large, relatively nonpolar groups. This chemical change increases the intrinsic hypoglycemic activity of the molecule 100-fold on a weight basis compared to first-generation agents. In addition, the pharmacokinetic properties, spectrum and severity of side effects and metabolism of this agent are somewhat different from those of first-generation sulfonylureas. The most important component of the antidiabetic action of glipizide is its effect in potentiating insulin action. Glipizide-mediated increases in nutrient-stimulated insulin secretion may contribute to its antidiabetic action. The drug is effective in controlling the blood glucose in patients with noninsulin-dependent diabetes mellitus. It is at least as effective as and probably more effective than first-generation sulfonylureas in controlling hyperglycemia in diabetes. Glipizide is relatively free of serious side effects and is contraindicated principally in patients with significant liver or kidney disease.